Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 5/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | PRCP | P42785 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25367907 | 0.80 | NOS3 (0.40) | NOS1ALDH1A1ALOX12KMT2AMAPT | |
| SCHEMBL2199447 | 0.75 | NOS1 (0.49) | NOS1ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL10041515 | 0.75 | NOS1 (0.49) | NOS1ALDH1A1HPGDKDM4EKMT2A | |
| SCHEMBL14251056 | 0.75 | NOS1 (0.49) | NOS1KDM4EMEN1KMT2AMAPT | |
| SCHEMBL29746270 | 0.75 | MEN1 (0.49) | NOS1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14720366 | 0.75 | MEN1 (0.49) | NOS1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL14720400 | 0.75 | MEN1 (0.49) | NOS1ALDH1A1KDM4EMEN1KMT2A | |
| SCHEMBL22201133 | 0.71 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EPKMALOX12 | |
| SCHEMBL6170474 | 0.71 | ALDH1A1 (0.39) | ALDH1A1HPGDKDM4EPKMALOX12 | |
| SCHEMBL11191557 | 0.69 | ALDH1A1 (0.45) | ALDH1A1HPGDRXFP1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2024-01-18 | — | — | US | disclosed |
| CN-116568675-A | Cyclic isothiourea derivatives as CXCR4 modulators | 埃尔米乌治疗公司 | 2023-08-08 | — | — | CN | disclosed |
| EP-4217353-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | Ermium Therapeutics (FR) | 2023-08-02 | — | — | EP | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-05-12 | — | — | US | disclosed |
| WO-2022064075-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | ERMIUM THERAPEUTICS (FR) | 2022-03-31 | — | — | WO | disclosed |
| EP-3947394-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2022-02-09 | — | — | EP | disclosed |
| CN-113939521-A | Imidazoline derivatives as CXCR4 modulators | 巴黎大学 | 2022-01-14 | — | — | CN | disclosed |
| WO-2020201096-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | Université de Paris (FR) | 2020-10-08 | — | — | WO | disclosed |
| US-7115748-B2 | Method of making imidazole-2-thiones | ALLERGAN, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20060122400-A1 | Method of making imidazole-2-thiones | ALLERGAN, INC. | 2006-06-08 | — | — | US | disclosed |
| US-4408072-A | Amido methoxyethylamines | AMERICAN CYANAMID COMPANY (US) | 1983-10-04 | — | — | US | disclosed |
| US-4370482-A | Synthesis of tetramisole, levamisole and their derivatives | AMERICAN CYANAMID CO. (US) | 1983-01-25 | — | — | US | disclosed |
| US-4316038-A | 1-(2-Methoxyethyl)-2-methyl-4-phenyl-2-imidazoline | AMERICAN CYANAMID COMPANY (US) | 1982-02-16 | — | — | US | disclosed |
| US-4314066-A | PREPARATION OF 1-(2-SUBSTITUTED ETHYL)-4-PHENYL-2-IMIDAZOLIDONES AND IMIDAZOLIDINE-2-THIONESC HYDROGENATION, CHIRAL CATALYST, HYDROLYSIS, SULFURIZATION | AMERICAN CYANAMID CO. (US) | 1982-02-02 | — | — | US | disclosed |
| US-4314079-A | Novel methoxyethylamine | AMERICAN CYANAMID COMPANY (US) | 1982-02-02 | — | — | US | disclosed |
| US-4245102-A | Processes for the preparation of tetramisole | AMERICAN CYANAMID COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
| US-4245103-A | Processes for the preparation of tetramisole | AMERICAN CYANAMID COMPANY (US) | 1981-01-13 | — | — | US | disclosed |
| US-4087611-A | CHEMICAL INTERMEDIATES | AMERICAN CYANAMID COMPANY (US) | 1978-05-02 | — | — | US | disclosed |
| US-RE29358-E | ANTI-MALARIA AND ANTI-TUBERCULOSIS AGENTS | AMERICAN CYANAMID COMPANY (US) | 1977-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144853-A1 | IMIDAZOLINE DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCL12, CXCR1 | NOS1 2543/4885ALDH1A1 2855/4885HPGD 1554/4885 |
| US-20240018125-A1 | CYCLIC ISOTHIOUREA DERIVATIVES AS CXCR4 MODULATORS | CXCR4, CXCR1, CXCL12 | NOS1 1471/4885ALDH1A1 2260/4885HPGD 1484/4885 |
| US-20060122400-A1 | Method of making imidazole-2-thiones | TST, INMT, TPMT | NOS1 211/4885ALDH1A1 382/4885HPGD 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.